Amgen Inc (AMGN) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Amgen Inc. is conducting a Phase 1 clinical study titled A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, Parallel Group Study With Nested Crossover Comparison to Assess the Effect of Maridebart Cafraglutide on QT/QTc Intervals in Participants Living With Overweight or Obesity. The study aims to evaluate the impact of maridebart cafraglutide on heart rate-corrected QT intervals in individuals with overweight or obesity, which is crucial for understanding the drug’s cardiac safety profile.
The study tests maridebart cafraglutide, a drug administered subcutaneously, intended to assess its effects on heart’s electrical activity. Moxifloxacin and placebos are also used for comparison.
This interventional study employs a randomized, crossover design with double masking, focusing on basic science to determine the drug’s safety and efficacy.
The study began on November 13, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on November 25, 2025, indicating ongoing recruitment.
For investors, this study could influence Amgen’s stock performance by potentially expanding its portfolio in the obesity treatment market. The outcome may also affect investor sentiment positively if results show a favorable safety profile, especially in comparison to competitors in the obesity drug market.
The study is currently recruiting, with more details available on the ClinicalTrials portal.
To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.